What is your background treating multiple myeloma? About how many patients would you say you see a year? Are these numbers changing year to year? Could you describe your typical patient?

What options do you currently use to treat your myeloma patients? Why do you consider them superior options to others?

The use of single arm studies in Phase 2 trials has garnered considerable caution from leading experts. How reasonable do you think the trial design of a single arm was in this Phase 2 study? Do 

The company mentions that management is unaware of any other agent having a comparable response to what KPT-3330 showed in this "penta" refractory population.  Do you know of other programs that have failed in this population? How strong are these results in your opinion.

If these results are clinically meaningful to you, then how likely is it that KPT-330 might be effective as an earlier treatment in MM?

Looking at inclusion criteria and baseline characteristics of the relevant studies, is it fair to compare these results for Selinexor (KPT-330) with the quad-refractory intravenous anti-CD38 therapy studies mentioned in the press release?

Selinexor has a reputation for toxicity and side effects.  How would you characterize the safety data from STORM and other trials, and can you comment on how well patients tolerate Selinexor?